AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34424530 — intervention group
Group type: COMPARATOR
Intervention: Decitabine monotherapy (control arm) in patients with white blood cell counts <10 × 10^9 /L
Number of subjects: 482
Study 32786002 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine receptor agonists (BZRAs)
Number of subjects: 797
Study 32786002 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 797
Study 32786002 — intervention group
Group type: EXPERIMENTAL
Intervention: BZRAs
Number of subjects: 797
Study 32786002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 797
Study 36208853 — intervention group
Group type: EXPERIMENTAL
Intervention: Typhoid vaccine
Number of subjects: 172
Study 36208853 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 172
Study 34181474 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically drug-resistant E. coli
Number of subjects: 187619
Study 34181474 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically drug-resistant K. pneumoniae
Number of subjects: 187619
Study 34181474 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically drug-resistant Acinetobacter baumannii
Number of subjects: 187619
Study 34181474 — intervention group
Group type: EXPERIMENTAL
Intervention: Critically drug-resistant Pseudomonas aeruginosa
Number of subjects: 187619
Study 34181474 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular characterization of carbapenemase genes
Number of subjects: 187619
Study 32442781 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (10 sessions)
Number of subjects: 162
Study 32442781 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 162
Study 35759874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media Intervention + Incentives for engagement
Number of subjects: 955
Study 35759874 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Media Intervention only
Number of subjects: 955
Study 35759874 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 955
Study 35759874 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentivized group
Number of subjects: 955
Study 35759874 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-incentivized group
Number of subjects: 955
Study 34559054 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted health program (exercise-based, automated chatbot messages via LINE for 12 weeks)
Number of subjects: 94
Study 34559054 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-assisted health program
Number of subjects: 94
Study 34559054 — intervention group
Group type: COMPARATOR
Intervention: Usual care routines (control group)
Number of subjects: 94
Study 36239914 — intervention group
Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg in fasted state
Number of subjects: 16
Study 36239914 — intervention group
Group type: EXPERIMENTAL
Intervention: Senaparib 100 mg in fed state
Number of subjects: 16
Study 36239914 — intervention group
Group type: COMPARATOR
Intervention: Safety profile in both states
Number of subjects: 16
Study 33862206 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic treatment (group 1), 13 patients, 2 required conversion to open surgery.
Number of subjects: 213
Study 33862206 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (group 2), 154 patients, 14 records compatible with laparoscopic criteria.
Number of subjects: 213
Study 32979074 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 g/day)
Number of subjects: 29
Study 32979074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 32979074 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + Exercise Training
Number of subjects: 29
Study 32979074 — intervention group
Group type: COMPARATOR
Intervention: Exercise Training Alone
Number of subjects: 29
Study 33299545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation delivered before major abdominal surgery
Number of subjects: 0
Study 33299545 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned)
Number of subjects: 0
Study 36266683 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4,000 units daily for 18 weeks)
Number of subjects: 88
Study 33684310 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mgI kg‐1 with 70 keV monochromatic images
Number of subjects: 40
Study 33684310 — intervention group
Group type: COMPARATOR
Intervention: 300 mgI kg‐1 with 40 keV monochromatic images
Number of subjects: 40
Study 33684310 — intervention group
Group type: COMPARATOR
Intervention: 300 mgI kg‐1 with 45 keV monochromatic images
Number of subjects: 40
Study 36224307 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial-anxiety condition (n = 22)
Number of subjects: 44
Study 36224307 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 22)
Number of subjects: 44
Study 34082251 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 hours post-PEG feeding (group 1)
Number of subjects: 97
Study 34082251 — intervention group
Group type: COMPARATOR
Intervention: 8 hours post-PEG feeding (group 2)
Number of subjects: 97
Study 32825990 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment (5 sessions over 8 weeks)
Number of subjects: 70
Study 32825990 — intervention group
Group type: COMPARATOR
Intervention: Control group (8-week untreated waiting period)
Number of subjects: 70
Study 36189565 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide eugenol
Number of subjects: 80
Study 36189565 — intervention group
Group type: EXPERIMENTAL
Intervention: Metapex
Number of subjects: 80
Study 34107963 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 511
Study 34107963 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (ASMQ)
Number of subjects: 511
Study 34107963 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day artemether-lumefantrine regimen (AL+)
Number of subjects: 511
Study 32247539 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 116
Study 32247539 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl boluses
Number of subjects: 116
Study 34215149 — intervention group
Group type: EXPERIMENTAL
Intervention: IMPULS treatment (8 weekly sessions)
Number of subjects: 24
Study 34215149 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 24
Study 35292989 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir plus interferon-beta (FVP + INF-beta)
Number of subjects: 66
Study 35292989 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir plus interferon-beta (LPV/RTV + INF-beta)
Number of subjects: 66
Study 34297338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg intravenously
Number of subjects: 97
Study 34297338 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 15 mg/kg intravenously
Number of subjects: 97
Study 34297338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin 25 mg/kg and 15 mg/kg
Number of subjects: 97
Study 32816094 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical activity and dietary intervention
Number of subjects: 504
Study 32816094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study 34810217 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus endocrine therapy (ET group, n = 196)
Number of subjects: 392
Study 34810217 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab plus chemotherapy (CT group, n = 196)
Number of subjects: 392
Study 35675677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobiderm compression bandage
Number of subjects: 50
Study 35675677 — intervention group
Group type: COMPARATOR
Intervention: Conventional multi-layered bandages
Number of subjects: 50
Study 34961541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvis-on group (robotic gait training with pelvic movements)
Number of subjects: 24
Study 34961541 — intervention group
Group type: COMPARATOR
Intervention: Pelvis-off group (robotic gait training without pelvic movements)
Number of subjects: 24
Study 32711414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Systems (H)
Number of subjects: 437
Study 32711414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Systems and Youth intervention (HY)
Number of subjects: 437
Study 32711414 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Systems, Community and Youth intervention (HCY)
Number of subjects: 437
Study 36259443 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked targets
Number of subjects: 1012
Study 36259443 — intervention group
Group type: EXPERIMENTAL
Intervention: Faces cropped to the eyes (Study 3)
Number of subjects: 1012
Study 36259443 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze into the eyes of faces (Study 4)
Number of subjects: 1012
Study 36259443 — intervention group
Group type: COMPARATOR
Intervention: Unmasked targets
Number of subjects: 1012
Study 34942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Melomics‐Health (MH) group (n = 20)
Number of subjects: 60
Study 34942921 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized music listening (IML) group (n = 20)
Number of subjects: 60
Study 34942921 — intervention group
Group type: COMPARATOR
Intervention: No music group (n = 20)
Number of subjects: 60
Study 33085058 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin 130 mg/m2 (SOX130)
Number of subjects: 63
Study 34261793 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC26.25 modified with three mutations in the CDRH3 region
Number of subjects: 0
Study 34261793 — intervention group
Group type: COMPARATOR
Intervention: Original VRC26.25 antibody
Number of subjects: 0
Study 32058608 — intervention group
Group type: EXPERIMENTAL
Intervention: Needleless administration of SCIT
Number of subjects: 0
Study 32058608 — intervention group
Group type: COMPARATOR
Intervention: Traditional administration of SCIT
Number of subjects: 0
Study 616511319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SWL
Number of subjects: 114
Study 616511319 — intervention group
Group type: COMPARATOR
Intervention: Fluoroscopy-guided SWL
Number of subjects: 114
Study 35021944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanocurcumin (80 mg/day for 8 weeks)
Number of subjects: 36
Study 34018809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 0
Study 34018809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 1837
Study 34526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg + MTX
Number of subjects: 1837
Study 34526397 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 1837
Study 34526397 — intervention group
Group type: EXPERIMENTAL
Intervention: ADA
Number of subjects: 1837
Study 34526397 — intervention group
Group type: COMPARATOR
Intervention: PBO
Number of subjects: 1837
Study 34526397 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 1837
Study 32139194 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Stabilized (MS) design
Number of subjects: 83
Study 32139194 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Stabilized (PS) design
Number of subjects: 83
Study 32139194 — intervention group
Group type: COMPARATOR
Intervention: Cruciate Retaining (CR) design
Number of subjects: 83
Study 32139194 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee Society Score 2011 Satisfaction
Number of subjects: 83
Study 33337698 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Exercise (HIIE, 1 minute 90% PPO followed by 1 minute 10% PPO, ×10)
Number of subjects: 30
Study 33337698 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Exercise (MOD, 20 minutes at 50% PPO)
Number of subjects: 30
Study 33337698 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprint-Interval Exercise (SPRT, 20 seconds 'all-out' sprints followed by 2 minutes at 50 W, ×3)
Number of subjects: 30
Study 33337698 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal Exercise Test (MAX)
Number of subjects: 30
Study 33308452 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ preservation with short-course radiotherapy followed by transanal endoscopic microsurgery
Number of subjects: 55
Study 33308452 — intervention group
Group type: COMPARATOR
Intervention: Total mesorectal excision
Number of subjects: 55
Study 33308452 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ preservation
Number of subjects: 55
Study 33308452 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-randomised organ preservation
Number of subjects: 55
Study 33308452 — intervention group
Group type: COMPARATOR
Intervention: Non-randomised total mesorectal excision
Number of subjects: 55
Study 33355713 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise in hypoxia (FIO2=0.15)
Number of subjects: 29
Study 33355713 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise in normoxia (FIO2=0.21)
Number of subjects: 29
Study 33890385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Stroke Unit (MSU)
Number of subjects: 440
Study 33890385 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ambulances (Control)
Number of subjects: 440
Study 32217612 — intervention group
Group type: EXPERIMENTAL
Intervention: ado-trastuzumab emtansine
Number of subjects: 0
Study 32217612 — intervention group
Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 0
Study 34432628 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilator strips (NDS)
Number of subjects: 54
Study 33812932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency (1 Hz) Repetitive Transcranial Magnetic Stimulation (rTMS) at the sensory-motor integration site (Cz) for 15 minutes
Number of subjects: 11
Study 33812932 — intervention group
Group type: EXPERIMENTAL
Intervention: Execution task (flexing and extending the index finger)
Number of subjects: 11
Study 33812932 — intervention group
Group type: EXPERIMENTAL
Intervention: Action observation task (watching a video of the same movement)
Number of subjects: 11
Study 33812932 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery task (imagining the flexion and extension of the index finger movement)
Number of subjects: 11
Study 32050858 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation (affirming values that are important to the participants)
Number of subjects: 352
Study 32050858 — intervention group
Group type: COMPARATOR
Intervention: No-affirmation condition
Number of subjects: 352
Study 32050858 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 352
Study 33726809 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational network intervention (MNI) delivered by case managers
Number of subjects: 60
Study 33726809 — intervention group
Group type: COMPARATOR
Intervention: Usual case manager support
Number of subjects: 60
Study 32020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise (IMX) - 6 months of supervised resistance/aerobic/impact exercise initiated at the onset of ADT
Number of subjects: 104
Study 32020032 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise (DEL) - 6 months of usual care followed by 6 months of resistance/aerobic/impact exercise
Number of subjects: 104
Study 32020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate exercise (IMX)
Number of subjects: 104
Study 32020032 — intervention group
Group type: COMPARATOR
Intervention: Delayed exercise (DEL)
Number of subjects: 104
Study 36104138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg on day 1 of the first week of each 8-week cycle, alternating with NIVO 480 mg monotherapy on day 1 of the fifth week of each 8-week cycle
Number of subjects: 106
Study 36104138 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 6 mg/kg plus Ipilimumab (IPI) 1 mg/kg
Number of subjects: 106
Study 34076752 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 104
Study 34076752 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (SWL)
Number of subjects: 104
Study 36154660 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral treatment for hepatitis C virus (HCV)
Number of subjects: 20
Study 33472789 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty+ intervention alongside standard care
Number of subjects: 76
Study 33472789 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 76
Study 36194846 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women (post‐MW) during postexercise muscle ischemia (PEMI)
Number of subjects: 31
Study 36194846 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women (pre‐MW) during postexercise muscle ischemia (PEMI)
Number of subjects: 31
Study 33158777 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal brachytherapy using 125I seed strand and CT‐guided percutaneous radioactive seed implantation therapy
Number of subjects: 21
Study 33158777 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with gemcitabine and cisplatin
Number of subjects: 21
Study 33158777 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous 125I seed implantation combined with insertion of radioactive strips through the biliary stent
Number of subjects: 21
Study 33095682 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel combined with trastuzumab plus lapatinib (THL)
Number of subjects: 305
Study 33095682 — intervention group
Group type: COMPARATOR
Intervention: Trastuzumab (TH)
Number of subjects: 305
Study 33095682 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (TL)
Number of subjects: 305
Study 33580520 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenobamate
Number of subjects: 0
Study 33580520 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital
Number of subjects: 0
Study 33580520 — intervention group
Group type: COMPARATOR
Intervention: Other alkyl-carbamates
Number of subjects: 0
Study 36475807 — intervention group
Group type: EXPERIMENTAL
Intervention: Scrotal Antegrade Sclerotherapy (SAS)
Number of subjects: 113
Study 36475807 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Palomo Surgery (LPS)
Number of subjects: 113
Study 33157269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use after legalization (2015)
Number of subjects: 39437
Study 33157269 — intervention group
Group type: COMPARATOR
Intervention: Cannabis use (any time)
Number of subjects: 39437
Study 32591274 — intervention group
Group type: EXPERIMENTAL
Intervention: L-PRF membranes
Number of subjects: 17
Study 32591274 — intervention group
Group type: COMPARATOR
Intervention: Control side (no L-PRF)
Number of subjects: 17
Study 33570225 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartAdapt DIR tool
Number of subjects: 32
Study 32507285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu laryngeal mask airway
Number of subjects: 70
Study 32507285 — intervention group
Group type: COMPARATOR
Intervention: I-gel®
Number of subjects: 70
Study 35841075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol‐based handrub gel with superfatting agents (Saniswiss Sanitizer Hands H1)
Number of subjects: 42
Study 35841075 — intervention group
Group type: COMPARATOR
Intervention: Isopropanol‐based formulations (Hopirub® or Hopigel®)
Number of subjects: 42
Study 33780276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemohormonal therapy and radical prostatectomy
Number of subjects: 656
Study 33780276 — intervention group
Group type: COMPARATOR
Intervention: Radical prostatectomy alone
Number of subjects: 656
Study 32826051 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of LVS using various surgical techniques including speculoscopy and septum excision with electrosurgical modalities, speculoscopy with laparoscopic devices, and vaginoscopy with hysteroscopic instruments.
Number of subjects: 121
Study 32826051 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginoscopic incision using resectoscope.
Number of subjects: 121
Study 36660974 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity multimodal exercise training (HIT-MMEX) - supervised resistance, weight-bearing, balance and mobility training twice weekly for 8 months
Number of subjects: 28
Study 36660974 — intervention group
Group type: COMPARATOR
Intervention: Low-to-moderate intensity exercises (Control group)
Number of subjects: 28
Study 34622862 — intervention group
Group type: EXPERIMENTAL
Intervention: Real LF-ThMS (30-minute session, pulsed magnetic field from 100 to 118 Hz, 10.5 to 13.1 milliTesla)
Number of subjects: 17
Study 34622862 — intervention group
Group type: COMPARATOR
Intervention: Sham LF-ThMS
Number of subjects: 17
Study 35405934 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal Nutrition (JN) with liquid nutrient (2 kcal/min) infused for 60 min prior to a standardized meal
Number of subjects: 30
Study 35405934 — intervention group
Group type: COMPARATOR
Intervention: Water (control) infused for 60 min prior to a standardized meal
Number of subjects: 30
Study 35405934 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal Nutrition (JN)
Number of subjects: 30
Study 35405934 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mixed solid/liquid test meal
Number of subjects: 30
Study 34461969 — intervention group
Group type: EXPERIMENTAL
Intervention: High PEEP ventilation strategy
Number of subjects: 3875
Study 34461969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-conservative strategy
Number of subjects: 3875
Study 34461969 — intervention group
Group type: COMPARATOR
Intervention: Phenotype I
Number of subjects: 3875
Study 34461969 — intervention group
Group type: COMPARATOR
Intervention: Phenotype II
Number of subjects: 3875
Study 34461969 — intervention group
Group type: COMPARATOR
Intervention: Phenotype III
Number of subjects: 3875
Study 32616309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane plus i.v. lidocaine (SL)
Number of subjects: 120
Study 32616309 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (S)
Number of subjects: 120
Study 32616309 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus i.v. lidocaine (PL)
Number of subjects: 120
Study 32616309 — intervention group
Group type: COMPARATOR
Intervention: Propofol (P)
Number of subjects: 120